Document Detail

Oral passive IgY-based immunotherapeutics: a novel solution for prevention and treatment of alimentary tract diseases.
MedLine Citation:
PMID:  23319156     Owner:  NLM     Status:  MEDLINE    
This commentary summarizes the laboratory investigations and clinical trials published recently involving per-oral application of IgY supplemented food for specific orogastrointestinal disease prevention and control purposes. The prolonged use and misuse of conventional antibacterial drugs has spawned antibiotic resistant microbes prompting scientists to search for other germ-killing options. In particular, the use of IgY as a novel mode of immunotherapy using oral chicken immunoglobulin (IgY) to confer passive immunity has gained much interest as an inexpensive non-antibiotic alternative for the prophylaxis and treatment of a wide variety of infectious diseases. The stability of IgY in the orogastrointestinal tract and its safety profile has been well-documented. IgY has been used in the treatment or prevention of dental caries, periodontitis and gingivitis, gastritis and gastric ulcer, oral thrush and infant rotavirus diarrhea. The recent clinical trials on IgY with encouraging results has catapulted into the market novel nutraceutical or health supplements for therapeutic or prophylactic intervention based on the consumption of mono-specific or mixed IgY formulations. With recent trends in consumer preference for natural materials to alleviate health concerns, the increasing healthcare costs and the recent advances in drug delivery systems, IgY is likely to shift from its mainly functional food status toward pharmaceuticalization in the foreseeable future.
Shofiqur Rahman; Sa Van Nguyen; Faustino C Icatlo; Kouji Umeda; Yoshikatsu Kodama
Related Documents :
23923496 - Day length, reproductive effort, and the avian latitudinal clutch size gradient.
23621086 - Selenium biotransformations in engineered aquatic ecosystem for bioremediation of agric...
23153136 - Effect of climate change and food insecurity on low-income households.
23576016 - Microbial diversity and dynamics of microbial communities during back-slop soaking of s...
20002546 - The reflect statement: methods and processes of creating reporting guidelines for rando...
23153286 - Food safety systems in a small dairy factory: implementation, major challenges, and ass...
Publication Detail:
Type:  Journal Article; Review     Date:  2013-01-14
Journal Detail:
Title:  Human vaccines & immunotherapeutics     Volume:  9     ISSN:  2164-554X     ISO Abbreviation:  Hum Vaccin Immunother     Publication Date:  2013 May 
Date Detail:
Created Date:  2013-10-07     Completed Date:  2014-05-05     Revised Date:  2014-10-09    
Medline Journal Info:
Nlm Unique ID:  101572652     Medline TA:  Hum Vaccin Immunother     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1039-48     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Oral
Clinical Trials as Topic
Communicable Diseases / therapy*
Digestive System Diseases / prevention & control*,  therapy*
Drug Evaluation, Preclinical
Immunization, Passive / methods*
Immunoglobulins / administration & dosage*,  immunology
Immunologic Factors / administration & dosage*,  immunology
Reg. No./Substance:
0/IgY; 0/Immunoglobulins; 0/Immunologic Factors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Post-training glucocorticoid receptor activation during Pavlovian conditioning reduces Pavlovian-ins...
Next Document:  Treatment of glioblastoma multiforme using a combination of small interfering RNA targeting epiderma...